Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Kyverna Therapeutics

Kyverna Therapeutics

Kyverna is a cell therapy company engineering a new class of curative living medicines for inflammatory and autoimmune diseases.

Kyverna Therapeutics is a cell therapy company developing therapies for autoimmune diseases. The company applies T cell engineering and synthetic biology technologies to develop therapies that aim to suppress and eliminate the autoreactive immune cells at the root of inflammatory diseases. Kyverna is collaborating with Gilead Sciences and received Series A investment from Vida Ventures, Westlake Village BioPartners and Gilead Sciences. Kyverna’s collaboration and licensing agreement with Gilead is for the development of engineered T cell therapies for treatment of autoimmune disease using Kyverna’s synthetic Treg platform and the synNotch technology from the Gilead company, Kite Pharma.

Timeline

January 26, 2022
Kyverna Therapeutics raises a $85,000,000 series B round from CAM Capital, Gilead Sciences, Hudson Bay Capital, Insight Partners, Intellia Therapeutics, LYFE Capital, Northpond Ventures, RTW Investments LLC, Vida Ventures, Westlake Village BioPartners and jVen Capital.
January 13, 2020
Kyverna Therapeutics raises a $25,000,000 series A round from Vida Ventures and Westlake Village BioPartners.
2018
Kyverna Therapeutics was founded by Jeffrey Greve.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Amirah Al Idrus
April 13, 2021
FierceBiotech
James Chung, a longtime Amgen executive who led global clinical development for autoimmune drug Enbrel, has a new gig. He joins Kyverna Therapeutics as chief medical officer as the company sets its sights on the clinic. Chung was most recently head of inflammation and neuroscience in Amgen's global medical organization and global development leader for Enbrel.
April 13, 2021
BioSpace
Kyverna Therapeutics Announces the Appointment of James Chung, M.D., Ph.D., as Chief Medical Officer - read this article along with other careers information, tips and advice on BioSpace
Kyverna Therapeutics
April 13, 2021
www.prnewswire.com:443
/PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced...

References

Golden logo
By using this site, you agree to our Terms & Conditions.